Streetbeat News

Regulatory

META

MSFT

TWTR

Elon Musk's rebranding of Twitter to 'X' could face legal challenges due to existing trademarks held by other companies, including Meta Platforms and Microsoft. Trademark attorney Josh Gerben estimates that the company could spend over $100 million in legal fees and settlement costs. Meta Platforms and Microsoft Corporation are among the companies that have intellectual property rights over the letter X. The X stock symbol belongs to United States Steel Corporation.

Portfolio Pulse from Chris Katje

July 27, 2023 | 12:58 pm

FEMY

Femasys Inc. (NASDAQ:FEMY) has received a Notice of Allowance from the US Patent and Trademark Office for its FemBloc permanent birth control product. The patent, when issued, is expected to expire in 2039. The company plans to continue to prosecute additional patent applications to further enhance its existing patent portfolio.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:46 pm

ITI

Iteris, Inc. (NASDAQ:ITI) has been selected to modernize public transit in Mérida, Mexico as part of a United States Trade and Development Agency (USTDA)-funded ITS modernization project. The project aims to update the bus control and monitoring center, and advance the transition to electric buses for Mérida's public transportation fleet. Iteris will support the selection and deployment of ITS technologies that will be critical to achieve the project's objectives.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:38 pm

ANIX

Anixa Biosciences, Inc. (NASDAQ:ANIX) has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its novel ovarian cancer vaccine technology. The patent, titled 'Ovarian Cancer Vaccines,' covers nucleic acid-based delivery of the vaccine. The technology is being developed in partnership with Cleveland Clinic. Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute (NCI).

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:37 pm

ATXI

Avenue Therapeutics, Inc. (NASDAQ:ATXI) has announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA). AJ201 is currently the lead drug candidate in the clinic for SBMA and enrollment in the trial is expected to be complete by the end of 2023 or early 2024 with potential topline data in 2024. The trial aims to demonstrate how AJ201's novel, multi-fold mechanism of action reduces accumulation of mutant AR aggregates to potentially decrease neuroinflammation, protect cells from oxidative stress, and ultimately, improve clinical outcomes for SBMA patients.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:32 pm

SPY

The Core PCE Prices for Q2 came in at 3.8%, lower than the expected 4%.

Portfolio Pulse from Bill Haddad

July 27, 2023 | 12:31 pm

SPY

The initial jobless claims in the USA have come in at 221K, which is lower than the estimated 235K and the prior figure of 228K.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:30 pm

VGK

The Euro Zone Marginal Lending Facility Rate has increased to 4.50% from the previous rate of 4.25%.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 12:25 pm

VGK

The Eurozone interest rate for July has been set at 4.25%, matching estimates and showing an increase from the previous rate of 4%.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 12:22 pm

VGK

The Euro Zone Deposit Facility Rate for July is reported at 3.75%, which is the same as the estimate but higher than the prior rate of 3.50%.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 12:20 pm